



## Cytokinetics Announces Three Upcoming Presentations at the American College of Cardiology 72nd Annual Scientific Session

February 24, 2023 9:00 PM EST

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three poster presentations at the American College of Cardiology 72<sup>nd</sup> Annual Scientific Session (ACC.23) taking place in New Orleans, LA from March 4, 2023 – March 6, 2023.

**Title:** 1560-153 - *Aficamten* in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)

**Presenter:** Ahmad Masri, M.D. M.S., Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University

**Session:** 1560 - Heart Failure and Cardiomyopathies: Clinical Science 11

**Date:** March 5, 2023

**Presentation Time:** 12:45 PM-1:30 PM Central Time

**Location:** Poster Hall, Hall F

**Title:** 1042-07 - Long-Term Efficacy and Safety of *Aficamten* in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy

**Presenter:** Sara Saberi, M.D., Associate Professor, Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan Health

**Session:** 1042 - Bulking Up: New Research in Hypertrophic Cardiomyopathy

**Date:** March 5, 2023

**Presentation Time:** 9:45-9:55 AM Central Time

**Location:** Heart Failure and Cardiomyopathies Moderated Poster Theater 11, Hall F

**Title:** 1279-169 - Applicability of the GALACTIC-HF Trial and *Omecamtiv Mecarbil* to Patients Hospitalized for Heart Failure in the United States: From the GWTG-HF Registry

**Presenter:** Josephine Harrington, M.D., Fellow, Division of Cardiology, Duke Clinical Research Institute, Duke University School of Medicine

**Session:** 1279 - Heart Failure and Cardiomyopathies: Clinical Science 3

**Date:** March 4, 2023

**Presentation Time:** 11:45-12:30 PM Central Time

**Location:** Poster Hall, Hall F

### About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of *omecamtiv mecarbil*, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing *aficamten*, a next-in-class cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of *aficamten* in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). *Aficamten* is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing *reldesemtiv*, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). In 2023, Cytokinetics is celebrating its 25-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit [www.cytokinetics.com](http://www.cytokinetics.com) and follow us on [Twitter](#), [LinkedIn](#), [Facebook](#) and [YouTube](#).

### Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our other clinical trials, statements relating to the potential benefits of *omecamtiv mecarbil*, *aficamten*, or any of our other drug candidates. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

### Contact:

Cytokinetics

Diane Weiser

Senior Vice President, Corporate Communications, Investor Relations

(415) 290-7757



Cytokinetics

Source: Cytokinetics, Incorporated